In January 2023, the 17th new patient was dosed with IMX-110 to date Positive safety data enabled continued dosing of previously enrolled patients Patients undergo CT scans every 8 weeks after dosing ...
Tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory ...
Immix Biopharma Inc (NASDAQ:IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE:BGNE) / Novartis AG's (NYSE:NVS) ...
IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab combination designed to enhance response to solid tumors by turning immunologically “cold” tumors “hot” Initial data anticipated in 1H 2023 LOS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results